<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419027</url>
  </required_header>
  <id_info>
    <org_study_id>CBT-GS14</org_study_id>
    <nct_id>NCT02419027</nct_id>
  </id_info>
  <brief_title>A Multi-center Human Study to Evaluate the Efficacy and Safety of ®GI Flora in Subjects With Irritable Bowel Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      A Multi-center, Randomized, Double-blinded, Placebo-controlled Human Study to Evaluate the&#xD;
      Efficacy and Safety of probiotic mixture(®GI Flora) in Subjects with Irritable Bowel&#xD;
      Syndrome.&#xD;
&#xD;
      Regimen: 6 probiotics mixture &gt;10^9/D for 8 weeks&#xD;
&#xD;
      Primary variable: visual analogue scale(VAS) assessment for abdominal pain&#xD;
&#xD;
      Secondary variable:&#xD;
&#xD;
        1. change of VAS score for abdominal pain/discomfort after 4/8-week treatment&#xD;
&#xD;
        2. daily symptom score for bloating, defecation discomfort(strain/urgency/incomplete&#xD;
           evacuation), flatulence , feces shape, frequency of bowel movements&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale for abdominal pain</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>GI Flora</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GI Flora</intervention_name>
    <arm_group_label>GI Flora</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Irritable bowel syndrome patients according to Rome III criteria&#xD;
&#xD;
          -  Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3&#xD;
             months associated with at least 2 of the following characteristics: a) improvement&#xD;
             with defecation; b) onset associated with a change in the frequency of stool; c) onset&#xD;
             associated with a change in form (appearance) of stool.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerable or hypersensitive to GI Flora.&#xD;
&#xD;
          -  Patients with active colon diverticulitis.&#xD;
&#xD;
          -  History of GI surgeries except hernia repair, appendectomy, primary closure due to&#xD;
             perforation.&#xD;
&#xD;
          -  History of inflammatory bowel disease, malignancy requiring surgery or chemotherapy or&#xD;
             radiation within 5 years.&#xD;
&#xD;
          -  Patient has any condition that, in the opinion of the Investigator, would compromise&#xD;
             the well-being of the patient or the requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GI Flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

